Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283399765> ?p ?o ?g. }
- W4283399765 endingPage "e489" @default.
- W4283399765 startingPage "e480" @default.
- W4283399765 abstract "<h2>Summary</h2><h3>Background</h3> Intra-articular botulinum toxin A injection might have analgesic effects in patients with joint diseases. We aimed to compare the effects of intra-articular botulinum toxin A injection with those of intra-articular saline injection for patients with painful base-of-thumb osteoarthritis. <h3>Methods</h3> RHIBOT was a double-blind, randomised, controlled, phase 3 trial conducted at Cochin Hospital, Paris, France. We recruited adult patients with x-ray evidence of trapeziometacarpal osteoarthritis who fulfilled the 1990 American College of Rheumatology criteria for hand osteoarthritis and reported a pain intensity score of at least 30 on an 11-point numeric rating scale (0: no pain to 100: maximal pain). Participants were randomly assigned (1:1), using a computer-generated randomisation list with permuted blocks of variable size (4 or 6), to receive an ultrasound-guided injection of either botulinum toxin A (50 Allergan units) in 1 mL of saline (experimental group) or 1 mL of saline alone (control group) in the trapeziometacarpal joint, in addition to custom-made rigid splinting. The primary outcome was the mean change from baseline in base-of-thumb pain in the previous 48 h on a numeric rating scale at 3 months after injection, analysed by intention to treat. This study is registered with ClinicalTrials.gov, NCT03187626. <h3>Findings</h3> Between Nov 2, 2018, and Nov 3, 2020, we assessed 370 individuals for eligibility and recruited 60 (16%) participants (mean age 64·9 years [SD 9·4], 47 [78%] women and 13 [22%] men), of whom 30 (50%) participants were randomly assigned to the experimental group and 30 (50%) to the control group. At baseline, base-of-thumb pain score was 60·0 of 100·0 (SD 15·9). At 3 months, the mean reduction in base-of-thumb pain was –25·7 (95% CI –35·5 to –15·8) in the experimental group and –9·7 (–17·1 to –2·2) in the control group (absolute difference –16·0 [–28·1 to –3·9]; p=0·043). Overall, 51 adverse events were reported in both groups: 27 (53%) in the experimental group and 24 (47%) in the control group. During follow-up, 14 (47%) participants in the experimental group and two (7%) participants in the control group reported mild transient motor deficit of the thenar muscle. No serious adverse events were reported. <h3>Interpretation</h3> Botulinum toxin A could be considered as a fast-acting, intra-articular therapy targeting chronic pain in individuals with base-of-thumb osteoarthritis. Future studies are needed to investigate the potential mechanism of the effects observed in this trial, to replicate our findings, and to assess the effects of repeated injections over time and their clinical effectiveness, including an analysis of cost-effectiveness. <h3>Funding</h3> Assistance Publique-Hôpitaux de Paris." @default.
- W4283399765 created "2022-06-25" @default.
- W4283399765 creator A5005915340 @default.
- W4283399765 creator A5019109126 @default.
- W4283399765 creator A5022334994 @default.
- W4283399765 creator A5025231768 @default.
- W4283399765 creator A5026961302 @default.
- W4283399765 creator A5027611835 @default.
- W4283399765 creator A5039461146 @default.
- W4283399765 creator A5042769560 @default.
- W4283399765 creator A5043474463 @default.
- W4283399765 creator A5043658114 @default.
- W4283399765 creator A5045691444 @default.
- W4283399765 creator A5047508694 @default.
- W4283399765 creator A5060560497 @default.
- W4283399765 creator A5062460121 @default.
- W4283399765 creator A5065380326 @default.
- W4283399765 creator A5080218048 @default.
- W4283399765 creator A5081271444 @default.
- W4283399765 creator A5087364937 @default.
- W4283399765 creator A5091698781 @default.
- W4283399765 date "2022-07-01" @default.
- W4283399765 modified "2023-10-02" @default.
- W4283399765 title "Intra-articular botulinum toxin A injection for painful base-of-thumb osteoarthritis: a double-blind, randomised, controlled, phase 3 trial (RHIBOT)" @default.
- W4283399765 cites W1975340194 @default.
- W4283399765 cites W1989476125 @default.
- W4283399765 cites W2009066073 @default.
- W4283399765 cites W2040105893 @default.
- W4283399765 cites W2042710584 @default.
- W4283399765 cites W2057647525 @default.
- W4283399765 cites W2066807621 @default.
- W4283399765 cites W2082777682 @default.
- W4283399765 cites W2089331060 @default.
- W4283399765 cites W2126607332 @default.
- W4283399765 cites W2135956897 @default.
- W4283399765 cites W2142055846 @default.
- W4283399765 cites W2157086964 @default.
- W4283399765 cites W2171767061 @default.
- W4283399765 cites W2341171155 @default.
- W4283399765 cites W2530841354 @default.
- W4283399765 cites W2706104770 @default.
- W4283399765 cites W2773573797 @default.
- W4283399765 cites W2803089126 @default.
- W4283399765 cites W2810827827 @default.
- W4283399765 cites W2888824226 @default.
- W4283399765 cites W2902669954 @default.
- W4283399765 cites W2973102014 @default.
- W4283399765 cites W2979413870 @default.
- W4283399765 cites W2986389123 @default.
- W4283399765 cites W3134374081 @default.
- W4283399765 cites W4211142475 @default.
- W4283399765 cites W4233138142 @default.
- W4283399765 cites W4236805817 @default.
- W4283399765 cites W4237427043 @default.
- W4283399765 doi "https://doi.org/10.1016/s2665-9913(22)00129-1" @default.
- W4283399765 hasPublicationYear "2022" @default.
- W4283399765 type Work @default.
- W4283399765 citedByCount "2" @default.
- W4283399765 countsByYear W42833997652022 @default.
- W4283399765 countsByYear W42833997652023 @default.
- W4283399765 crossrefType "journal-article" @default.
- W4283399765 hasAuthorship W4283399765A5005915340 @default.
- W4283399765 hasAuthorship W4283399765A5019109126 @default.
- W4283399765 hasAuthorship W4283399765A5022334994 @default.
- W4283399765 hasAuthorship W4283399765A5025231768 @default.
- W4283399765 hasAuthorship W4283399765A5026961302 @default.
- W4283399765 hasAuthorship W4283399765A5027611835 @default.
- W4283399765 hasAuthorship W4283399765A5039461146 @default.
- W4283399765 hasAuthorship W4283399765A5042769560 @default.
- W4283399765 hasAuthorship W4283399765A5043474463 @default.
- W4283399765 hasAuthorship W4283399765A5043658114 @default.
- W4283399765 hasAuthorship W4283399765A5045691444 @default.
- W4283399765 hasAuthorship W4283399765A5047508694 @default.
- W4283399765 hasAuthorship W4283399765A5060560497 @default.
- W4283399765 hasAuthorship W4283399765A5062460121 @default.
- W4283399765 hasAuthorship W4283399765A5065380326 @default.
- W4283399765 hasAuthorship W4283399765A5080218048 @default.
- W4283399765 hasAuthorship W4283399765A5081271444 @default.
- W4283399765 hasAuthorship W4283399765A5087364937 @default.
- W4283399765 hasAuthorship W4283399765A5091698781 @default.
- W4283399765 hasBestOaLocation W42833997651 @default.
- W4283399765 hasConcept C141071460 @default.
- W4283399765 hasConcept C142724271 @default.
- W4283399765 hasConcept C1862650 @default.
- W4283399765 hasConcept C204787440 @default.
- W4283399765 hasConcept C27081682 @default.
- W4283399765 hasConcept C2776164576 @default.
- W4283399765 hasConcept C2776881184 @default.
- W4283399765 hasConcept C2777478456 @default.
- W4283399765 hasConcept C2991744798 @default.
- W4283399765 hasConcept C42219234 @default.
- W4283399765 hasConcept C71924100 @default.
- W4283399765 hasConcept C99508421 @default.
- W4283399765 hasConceptScore W4283399765C141071460 @default.
- W4283399765 hasConceptScore W4283399765C142724271 @default.
- W4283399765 hasConceptScore W4283399765C1862650 @default.
- W4283399765 hasConceptScore W4283399765C204787440 @default.
- W4283399765 hasConceptScore W4283399765C27081682 @default.